 TORONTO--BUSINESS WIRE--FSD Pharma Inc. Nasdaq: HUGE CSE: HUGE FSD Pharma or the Company today announces the following corporate updates. Corporate Update The Company continues to pursue its strategy of completing a Phase 2 clinical trial for the use of its lead compound, ultramicronized-palmitoylethanolamide or ultramicronized PEA FSD201, to treat hospitalized COVID-19 patients in a double-blind study the Study. The Company is expected to randomize 352 patients with COVID 